Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
The stock option will vest over a four-year period, with
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230707807146/en/
Investor:
Gitanjali Jain
Vice President, Investor Relations and External Affairs
gjain@kezarbio.com
Media:
Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystrat.com
Source: Kezar Life Sciences, Inc.